HLS vs. TLRY, ACB, WEED, FIRE, EPI, OGI, ICC, CPH, RIV, and LEAF
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Tilray Brands (TLRY), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), ICC Labs (ICC), Cipher Pharmaceuticals (CPH), RIV Capital (RIV), and Leaf Mobile (LEAF). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs.
Tilray Brands (TSE:TLRY) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.
HLS Therapeutics received 34 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 64.15% of users gave HLS Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote.
HLS Therapeutics has lower revenue, but higher earnings than Tilray Brands. HLS Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Tilray Brands has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
11.2% of Tilray Brands shares are owned by institutional investors. Comparatively, 65.2% of HLS Therapeutics shares are owned by institutional investors. 0.7% of Tilray Brands shares are owned by company insiders. Comparatively, 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tilray Brands has a net margin of -30.02% compared to HLS Therapeutics' net margin of -38.70%. Tilray Brands' return on equity of -7.24% beat HLS Therapeutics' return on equity.
HLS Therapeutics has a consensus price target of C$4.50, indicating a potential downside of 3.23%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe HLS Therapeutics is more favorable than Tilray Brands.
In the previous week, HLS Therapeutics had 2 more articles in the media than Tilray Brands. MarketBeat recorded 3 mentions for HLS Therapeutics and 1 mentions for Tilray Brands. HLS Therapeutics' average media sentiment score of 1.12 beat Tilray Brands' score of 0.59 indicating that HLS Therapeutics is being referred to more favorably in the news media.
Summary
HLS Therapeutics beats Tilray Brands on 9 of the 17 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 5/23/2025 by MarketBeat.com Staff